Rationale and design of a clinical trial of a low-molecular-weight heparin in preventing clinically important venous thromboembolism in medical patients: the Prospective Evaluation of Dalteparin efficacy for Prevention of Venous Thromboembolism in Immobilized Patients Trial (the PREVENT study)

Abstract

The utility of low-molecular-weight heparin (LMWH) in the prophylaxis of venous thromboembolic disease has been examined using the surrogate endpoint of venographically identified thrombi. The largest portion of these thrombi were asymptomatic calf-vein thrombi. The clinical relevance of this observation is a matter of debate. The present study is designed to evaluate the impact of an LMWH on clinically important endpoints.

The current study is a randomized, prospective, double-blinded, multicenter, multinational, controlled clinical trial comparing dalteparin with placebo in moderately high-risk hospitalized medical patients. A total of 3300 patients will be randomized to receive either 5000 IU per day of dalteparin or placebo for 14 days. Patients will undergo appropriate evaluation for any symptomatic episodes and all patients will undergo a bilateral compression ultrasound (CUS) on day 21 to search for asymptomatic proximal thrombi.

The primary endpoint is the combination of objectively confirmed symptomatic deep vein thrombi (DVT), fatal or non-fatal pulmonary emboli, all proximal DVT, and sudden death.

This study will be the first study to examine clinically important endpoints in evaluating the effect of a LMWH in hospitalized medical patients. This study also is the first study to use CUS rather than venography in concordance with contemporary medical practice. This trial is thus designed to address this important question in a clinically relevant manner.

Keywords

dalteparin deep vein thrombosis prophylaxis pulmonary embolism venous thromboembolism

References

Cohen AT. Venous thromboembolic disease management of the non- surgical moderate- and high-risk patient. Semin Hematol 2000; 37 (suppl 5): 19-22.

Bergqvist D , Burmark US , Flordal PA et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995; 82: 496-501.

Bergqvist D , Burmark US , Frisell J et al. Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgey: a comparison with low-dose heparin. Semin Thromb Hemost 1990; 16(suppl): 19-24.

Erikkson BI , Kalebo P , Anthmyr BA , Wadenvik H , Tengborn L , Risberg B. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement: comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am 1991; 73-A: 484-493.

Hull RD , Pineo GF , Francis C et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med 2000; 160: 2208-2215.

Geerts WH , Heit JA , Clagett PG et al. Prevention of venous thromboembolism. Chest 2001; 119 (suppl): 132S-175S.

Mismetti P , Laporte-Simitsidis S , Tardy B et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83: 14-19.

Samama MM , Cohen AT , Darmon JY et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely Ill medical patients. N Engl J Med 1999; 341: 793-800.

The PIOPED investigators . Value of the ventilation/perfusion scan in acute pulmonary embolism. Result of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA 1990; 263: 2753-2759.

10.

Prentice CR.

Are symptomatic endpoints acceptable in venous thromboprophylactic studies?

Haemostasis 1998; 28 (suppl 3): 109-112.

11.

Dh te R , Pellicer-Coeuret M , Belouet-Moreau C , Christoforov B , Vidal-Trecan G. Venous thromboembolism in medical inpatients: prophylaxis with low-weight heparin in a university hospital and prevalence of thromboembolic events. Clin Appl Thromb Hemost 2001; 7: 16-20.

12.

Ellenberg SS , Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Ann Intern Med 2000; 133: 464-470.

13.

Emanuel EJ , Miller FG. The ethics of placebo-controlled trials - a middle ground. N Engl J Med 2001; 345: 915-919.

14.

Kearon C , Ginsberg JS , Hirsh J. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med 1998; 129: 1044-1049.